The possibility that chemerin-mediated recruitment of immune effectors to the tumor microenvironment contributes to poor prognosis via the promotion of BCSC phenotype is an intriguing possibility that remains to be experimentally tested. The gene discussed is RARRES2; the disease is neoplasm.